The effect of anti-inflammatory formula to reduce inflammation in intensive care unit patients

The effect of low Dietary Inflammatory Index formula on inflammatory and metabolic biomarkers in multiple trauma patients in Intensive Care Unit: a single blind randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180515039674N1

Enrollment

Registered

2018-09-04

Start date

2018-06-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple truama. Injury, poisoning and certain other consequences of external causes

Interventions

Intervention 1: Intervention group: To receive eternal formula (gavage) with low inflammation profile (anti-inflammation) for two weeks. Intervention 2: Control group: To receive standard eternal form

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: age between 18-65 Gastrointestinal tract with normal function and indications of Entral Nutrition Diagnosis of moderate to severe trauma based on GCS (4-14)

Exclusion criteria

Exclusion criteria: failure to start enteral nutrition during the first 48 hours of admission Any history of cardiovascular disease Patients who are less than 96 hours in intensive care unit. Patients who are predicted to die within 12 hours of admission to the intensive care unit. Patients who are contraindicated for receiving enteral nutrition Patient dissatisfaction or their legal guardian

Design outcomes

Primary

Measure	Time frame
Tumor necrosis factor-a. Timepoint: at the baseline, 7 and 14 days after intervention. Method of measurement: Enzyme-linked immunosorbent assay.;Hs-CRP. Timepoint: at the baseline, 7 and 14 days after intervention. Method of measurement: Enzyme-linked immunosorbent assay.	—

Secondary

Measure	Time frame
Alkaline phosphatase. Timepoint: At the baseline and 14 days after starting intervention. Method of measurement: Auto-analyzer.;Aspartate Aminotransferase. Timepoint: At the baseline and 14 days after starting intervention. Method of measurement: Auto-analyzer.;Alanine Aminotransferase. Timepoint: At the baseline and 14 days after starting intervention. Method of measurement: Auto-analyzer.;Blood Glucose. Timepoint: At the baseline and 14 days after starting intervention. Method of measurement: Auto-analyzer.;Triglyceride. Timepoint: At the baseline and 14 days after starting intervention. Method of measurement: Auto-analyzer.	—

Measure

Time frame

Alkaline phosphatase. Timepoint: At the baseline and 14 days after starting intervention. Method of measurement: Auto-analyzer.;Aspartate Aminotransferase. Timepoint: At the baseline and 14 days after starting intervention. Method of measurement: Auto-analyzer.;Alanine Aminotransferase. Timepoint: At the baseline and 14 days after starting intervention. Method of measurement: Auto-analyzer.;Blood Glucose. Timepoint: At the baseline and 14 days after starting intervention. Method of measurement: Auto-analyzer.;Triglyceride. Timepoint: At the baseline and 14 days after starting intervention. Method of measurement: Auto-analyzer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSajedeh Jandari

Mashhad University of Medical Sciences

Jandaris951@mums.ac.ir+98 51 3882 7034

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026